ARCHIVES

Regulatory Approvals: FDA expanded the approved use of Cyramza to include metastatic NSCLC

This article is from The Cancer Letter archive.

Vol. 40 No. 47 | December 19, 2014

Download PDF Visit The Full Archive

Related Articles

IARC Says Evidence Supports Mammography Screening For 50-69, Limited Evidence For 40-49

March 22, 2002

In Brief: Grand Jury To Consider Charges Against N.M. Community Based Cancer Program Staff Members

January 4, 1980

Center Program Move Definite; DCBD to Be Renamed

September 22, 1989

DCT Board Approves Concept For BRMP Master Agreement

June 26, 1987

Blood Vessel Growth Inhibitor May Be Tested Against KS

August 16, 1991

Counter-Point: George Sledge Responds To Berry’s Letter: Neoadjuvant Doesn’t Predict Adjuvant In Breast Cancer

July 11, 2014